Citations

Clear

249 citation(s) found for "St-Denis, L".

Application of Deep Learning Models to Improve Ulcerative Colitis Endoscopic Disease Activity Scoring Under Multiple Scoring Systems
Iacucci, Marietta , Parsa, Nasim , Reddy, D. Nageshwar , Rughwani, Hardik , Singh, Aniruddha Pratap , Monsurate, R, Soudan, Florian, Laage, Greta, Cremonese, Enrico D, St-Denis, L, Lemaître, Paul, Nikfal, Shima, Asselin, J, Henkel, Milagros L, Iacucci, Marietta , Byrne, Michael F. , Panaccione, Remo , East, James E. , Kalapala, Rakesh , Berry, Sameer , Cremonese, Enrico D., Henkel, Milagros L., Travis, Simon

Mayo Clinic

Journal of Crohn's and Colitis | October 17, 2022 | Volume: 17 | Issue: 4 | Pages: 463-471

10.1093/ecco-jcc/jjac152 | PMID 36254822 Get It

Abstract Background and Aims Lack of clinical validation and inter-observer variability are two limitations of endoscopic assessment and scoring of disease severity in patients with ulcerative colitis [UC]. We developed a deep learning [DL] model to improve, accelerate and automate UC detection, and predict the Mayo Endoscopic Subscore [MES] and the Ulcerative Colitis Endoscopic Index of Severity [UCEIS]. Methods A total of 134 prospective videos [1550 030 frames] were collected and those with poor quality were excluded. The frames were labelled by experts based on MES and UCEIS scores. The scored frames were used to create a preprocessing pipeline and train multiple convolutional neural networks [CNNs] with proprietary algorithms in order to filter, detect and assess all frames. These frames served as the input for the DL model, with the output being continuous scores for MES and UCEIS [and its components]. A graphical user interface was developed to support both labelling video sections and displaying the predicted disease severity assessment by the artificial intelligence from endoscopic recordings. Results Mean absolute error [MAE] and mean bias were used to evaluate the distance of the continuous model’s predictions from ground truth, and its possible tendency to over/under-predict were excellent for MES and UCEIS. The quadratic weighted kappa used to compare the inter-rater agreement between experts’ labels and the model’s predictions showed strong agreement [0.87, 0.88 at frame-level, 0.88, 0.90 at section-level and 0.90, 0.78 at video-level, for MES and UCEIS, respectively]. Conclusions We present the first fully automated tool that improves the accuracy of the MES and UCEIS, reduces the time between video collection and review, and improves subsequent quality assurance and scoring.
Two FTD-ALS genes converge on the endosomal pathway to induce TDP-43 pathology and degeneration
Shao, Wei , Todd, Tiffany W. , Wu, Yanwei , Jones, Caroline Y. , Tong, Jimei, Jansen‐West, Karen , Daughrity, Lillian M. , Park, Jinyoung , Koike, Yuka , Kurti, Aishe, Yue, Mei, Castanedes‐Casey, Monica , Rosso, Giulia del, Dunmore, Judith A. , Alepuz, Desiree Zanetti , Oskarsson, Björn , Cook, Casey , Prudencio, Mercedes , Fryer, John Denis , Zhang, Yong‐Jie , Petrucelli, Leonard , Del Rosso, Giulia, Zanetti Alepuz, Desiree, Dickson, Dennis W , Cook, Casey N , Prudencio, Mercedes , Gendron, Tania F , Zhang, Yong-Jie , Petrucelli, Leonard , Oskarsson, Björn , Shao, Wei , Koike, Yuka , Dickson, Dennis W. , Gendron, Tania F.

Mayo Clinic

Science | October 6, 2022 | Volume: 378 | Issue: 6615 | Pages: 94-99

10.1126/science.abq7860 | PMID 36201573 Get It

Frontotemporal dementia and amyotrophic lateral sclerosis (FTD-ALS) are associated with both a repeat expansion in the C9orf72 gene and mutations in the TANK-binding kinase 1 ( TBK1 ) gene. We found that TBK1 is phosphorylated in response to C9orf72 poly(Gly-Ala) [poly(GA)] aggregation and sequestered into inclusions, which leads to a loss of TBK1 activity and contributes to neurodegeneration. When we reduced TBK1 activity using a TBK1-R228H (Arg 228 →His) mutation in mice, poly(GA)-induced phenotypes were exacerbated. These phenotypes included an increase in TAR DNA binding protein 43 (TDP-43) pathology and the accumulation of defective endosomes in poly(GA)-positive neurons. Inhibiting the endosomal pathway induced TDP-43 aggregation, which highlights the importance of this pathway and TBK1 activity in pathogenesis. This interplay between C9orf72 , TBK1 , and TDP-43 connects three different facets of FTD-ALS into one coherent pathway.
How We Look At Mature Faces—An Eye-Tracking Investigation Into the Perception of Age
Frank, Konstantin , Ehrl, Denis , Bernardini, Francesco P. , Walbrun, Alina, Alfertshofer, Michael , Davidović, Kristina , Alfertshofer, Michael , Moellhoff, Nicholas , Mardini, Samir , Gotkin, Robert H. , Cotofana, Sebastian

Mayo Clinic

Aesthetic Surgery Journal | September 13, 2022 | Volume: 43 | Issue: 2 | Pages: 115-122

10.1093/asj/sjac251 | PMID 36099471 Get It

Abstract Background It is still unclear which facial region contributes most to the perception of an aged face when evaluated by eye-tracking analyses. Objectives The authors sought to apply eye-tracking technology to identify whether mature faces require longer fixation durations than young faces and which facial region contributes most to the perception of a mature face. Methods Eye-tracking analyses were conducted in 74 volunteers (37 males, 37 females; 43 ≤ 40 years, 31 > 40 years) evaluating their gaze pattern and the fixation durations for the entire face and 9 facial subregions. Frontal facial images of 16 younger (<40 years) and older (>40 years) gender-matched individuals were presented in a standardized setting. Results Independent of age or gender of the observer, a younger stimulus image was viewed shorter than an older stimulus image with 0.82 (0.63) seconds vs 1.06 (0.73) seconds with P < 0.001. There was no statistically significant difference in their duration of a stable eye fixation when observers inspected a male vs a female stimulus image [0.94 (0.70) seconds vs 0.94 (0.68) seconds; P = 0.657] independent of the observer’s age or gender. The facial image that captured the most attention of the observer (rank 9) was the perioral region with 1.61 (0.73) seconds for younger observers and 1.57 (0.73) seconds for older observers. Conclusions It was revealed that the perioral region attracts the most attention of observers and contributes most to an aged facial appearance. Practitioners should be mindful of the importance of the perioral region when designing an aesthetic treatment plan.
Surgical treatment of brain arteriovenous malformations: clinical outcomes of patients included in the registry of a pragmatic randomized trial
Darsaut, Tim E. , Magro, Elsa, Bojanowski, Michel W., Chaalala, Chiraz , Nico, Lorena , Bacchus, Emma, Klink, Ruby , Sabatier, Jean-François, Januel, Anne-Christine , Pélissou-Guyotat, I., Roche, Pièrre-Hugues , Brunel, Hervé, Proust, F. , Cornu, Philippe, Gaberel, Thomas , Barbier, Charlotte , Corre, Marine Le, Costalat, Vincent , Jecko, Vincent , Barreau, Xavier , Gauvrit, Jean‐Yves , Derrey, Stéphane , Papagiannaki, Chrysanthi , Abdalkader, Mohamad , Viard, Geraldine, Raymond, Jean , _, _, _, _, Chow, Michael M. C., Findlay, J. Max , Lesiuk, Howard , Drake, Brian , Santos, Marlene dos, Seizeur, Romuald, Pradier, Olivier, Ognard, Julien, Aouni, Mourad Cheddad El , Boursier, Romain, Thillays, F. , Roualdes, Vincent , Calvière, Lionel , Gauvrit, J.Y., Lecouillard, Isabelle, Nouhaud, Elodie, Raoult, Hélène , Eugene, François, Paya, Christophe, Ronzière, Thomas , Trystram, D. , Naggara, Olivier, Emery, Évelyne , Pellisou-Guyotat, Isabelle, Guyotat, Jacques, Berhouma, Monsef, Riva, Roberto, Biondi, Alessandra , Thines, L. , Bougaci, Nassim , Bracard, Serge, Anxionnat, René , Bernier‐Chastagner, Valérie , Civit, Thierry, Penchet, Guillaume, Gimbert, Edouard, Marnat, Gaulthier, Huchet, Aymeri, Herbreteau, Denis , Bibi, Richard, Ifergan, Héloïse , Janot, Kévin, Peyrière, Hadrien, Kaya, Jean-Marc, Touta, Adamou, Troude, Lucas, Boissonneau, Sébastien , Boch, Anne‐Laure , Clarençon, Frédéric , Nouet, Aurélien , Premat, Kévin, Gascou, Gregory, Lefevre, Pierre-Henri, Riquelme, Carlos , Cébula, H. , Ollivier, Irène , Pop, Raoul, Spatola, Giorgio, Chalumeau, Vanessa, Ikka, Léon , Ozanne, Augustin , Caroff, Jildaz, Chabert, Emmanuel , Rouchaud, Aymeric, Caire, François, Ricolfi, F. , Cao, Catherine, Mourier, Klaus-Luc, Thouant, Pierre, Farah, Walid, Carlson, Andrew P. , Silva, Luciana Alves Oliveira, Froio, Nayara de Lima, Mont’Alverne, Francisco J. A., Martins, Jose Luri, Mendes, George Nilton Nunes , Miranda, Rodrigo Rivera, Rouchaud, Aymeric , Rivera, Rodrigo , Ognard, Julien , Shotar, Eimad , Rouchaud, Aymeric , Ognard, Julien , Bojanowski, Michel W. , Iancu, Daniela , Weill, Alain , Roy, Daniel C. , Cognard, Christophe , Eker, Omer , Graillon, Thomas , Beaujeux, Rémy , Aldéa, Sorin , Piotin, Michel , Shotar, Eimad , Corre, Marine Le, Morandi, Xavier , Nguyen, Thanh N. , Tawk, Rabih G. , Huynh, Thien , Gévry, Guylaine , Gentric, Jean‐Christophe , _, _, _, _, Rempel, Jeremy L , O'Kelly, Cian J , Fahed, Robert , Santos, Marlene dos, Nonent, Michel , Timsit, Serge , Desal, Hubert , Blanc, Raphaël , Eugene, François, Bras, Anthony Le , Ferré, Jean‐Christophe , Paya, Christophe, Rodriguez-Régent, Christine , Kerleroux, Basile , Touzé, Emmanuel , Dumot, Chloé , Charbonnier, Guillaume , Gory, Benjamin , Boulouis, Grégoire , Velut, Stéphane , Bibi, Richard , Troude, Lucas , Sourour, Nader Antoine , Lenck, Stéphanie , Premat, Kévin , Corre, Marine Le, Bonafé, Alain , Dargazanli, Cyril , Gascou, Grégory , Lefèvre, Pierre-Henri , Pop, Raoul , Spelle, Laurent , Chalumeau, Vanessa , Gallas, Sophie , Mihalea, Cristian , Mounayer, Charbel , Thouant, Pierre , Silva, Gisele Sampaio , Montalverne, Francisco Jose

Mayo Clinic

Journal of Neurosurgery | September 9, 2022 | Volume: 138 | Issue: 4 | Pages: 891-899

10.3171/2022.7.jns22813 | PMID 36087316 Get It

OBJECTIVE The Treatment of Brain Arteriovenous Malformations Study (TOBAS) is a pragmatic study that includes 2 randomized trials and registries of treated or conservatively managed patients. The authors report the results of the surgical registry. METHODS TOBAS patients are managed according to an algorithm that combines clinical judgment and randomized allocation. For patients considered for curative treatment, clinicians selected from surgery, endovascular therapy, or radiation therapy as the primary curative method, and whether observation was a reasonable alternative. When surgery was selected and observation was deemed unreasonable, the patient was not included in the randomized controlled trial but placed in the surgical registry. The primary outcome of the trial was mRS score > 2 at 10 years (at last follow-up for the current report). Secondary outcomes include angiographic results, perioperative serious adverse events, and permanent treatment-related complications leading to mRS score > 2. RESULTS From June 2014 to May 2021, 1010 patients were recruited at 30 TOBAS centers. Surgery was selected for 229/512 patients (44%) considered for curative treatment; 77 (34%) were included in the surgery versus observation randomized trial and 152 (66%) were placed in the surgical registry. Surgical registry patients had 124/152 (82%) ruptured and 28/152 (18%) unruptured arteriovenous malformations (AVMs), with the majority categorized as low-grade Spetzler-Martin grade I–II AVM (118/152 [78%]). Thirteen patients were excluded, leaving 139 patients for analysis. Embolization was performed prior to surgery in 78/139 (56%) patients. Surgical angiographic cure was obtained in 123/139 all-grade (89%, 95% CI 82%–93%) and 105/110 low-grade (95%, 95% CI 90%–98%) AVM patients. At the mean follow-up of 18.1 months, 16 patients (12%, 95% CI 7%–18%) had reached the primary safety outcome of mRS score > 2, including 11/16 who had a baseline mRS score ≥ 3 due to previous AVM rupture. Serious adverse events occurred in 29 patients (21%, 95% CI 15%–28%). Permanent treatment-related complications leading to mRS score > 2 occurred in 6/139 patients (4%, 95% CI 2%–9%), 5 (83%) of whom had complications due to preoperative embolization. CONCLUSIONS The surgical treatment of brain AVMs in the TOBAS registry was curative in 88% of patients. The participation of more patients, surgeons, and centers in randomized trials is needed to definitively establish the role of surgery in the treatment of unruptured brain AVMs. Clinical trial registration no.: NCT02098252 (ClinicalTrials.gov)
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
Lassman, Andrew B. , Hoang‐Xuan, Khê , Polley, Mei‐Yin C. , Cairncross, J. Gregory , Ashby, Lynn S., Taphoorn, Martin , Souhami, Luís, Dinjens, Winand N.M. , Kouwenhoven, Mathilde C.M. , Fink, Karen, French, Pim J. , Macdonald, David R., Lacombe, Denis , Won, Minhee , Gorlia, Thierry, Bent, Martin J. van den , Taphoorn, Martin J B , Dinjens, Winand N M , Laack, Nadia N Issa , Kouwenhoven, Mathilde C M , French, Pim J , Mehta, Minesh P , van den Bent, Martin J , Brandes, Alba Ariela , Kros, Johan M. , Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | June 22, 2022 | Volume: 40 | Issue: 23 | Pages: 2539-2545

10.1200/jco.21.02543 | PMID 35731991 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the basis of the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Anaplastic oligodendroglial tumors (AOTs) are chemotherapy-sensitive brain tumors. We report the final very long-term survival results from European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 phase III trials initiated in 1990s, which both studied radiotherapy with/without neo/adjuvant procarbazine, lomustine, and vincristine (PCV) for newly diagnosed anaplastic oligodendroglial tumors. The median follow-up duration in both was 18-19 years. For European Organization for the Research and Treatment of Cancer 26951, median, 14-year, and probable 20-year overall survival rates without versus with PCV were 2.6 years, 13.4%, and 10.1% versus 3.5 years, 25.1%, and 16.8% (N = 368 overall; hazard ratio [HR] 0.78; 95% CI, 0.63 to 0.98; P = .033), with 1p19q codeletion 9.3 years, 26.2%, and 13.6% versus 14.2 years, 51.0%, and 37.1% (n = 80; HR 0.60; 95% CI, 0.35 to 1.03; P = .063), respectively. For Radiation Therapy Oncology Group 9402, analogous results were 4.8 years, 16.5%, and 11.2% versus 4.8 years, 29.1%, and 24.6% (N = 289 overall; HR 0.79; 95% CI, 0.61 to 1.03; P = .08), with codeletion 7.3 years, 25.0%, and 14.9% versus 13.2 years, 46.1%, and 37% (n = 125; HR 0.61; 95% CI, 0.40 to 0.94; P = .02), respectively. With that, the studies show similar long-term survival even without tumor recurrence in a significant proportion of patients after first-line treatment with radiotherapy/PCV.
A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non–small cell lung cancer (NSCLC).
Camidge, D. Ross , Jänne, Pasi A. , Rehman, Muneeb, Pachter, Jonathan A. , Patrick, Gloria, Denis, Louis J., Reuss, Joshua E. , Spira, Alexander I. , Patrick, Gloria, Spigel, David R.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS9147-TPS9147

10.1200/jco.2022.40.16_suppl.tps9147 Get It

TPS9147 Background: KRAS is mutated (mt) in 25% of NSCLC adenocarcinoma, with KRAS G12V and G12C mt occurring in ̃7% and ̃13% of patients (pts), respectively. Whereas G12C inhibitors have demonstrated promising activity in pts with KRAS G12C NSCLC, KRAS G12V NSCLC remains an unmet need. BRAF mt occurs in ̃4% of NSCLC with roughly equal split between BRAF V600E and non-V600E. VS-6766 is a small molecule RAF/MEK clamp that inhibits BRAF, CRAF and MEK, enabling VS-6766 to block MEK signaling without compensatory activation of MEK observed with MEK-only inhibitors. VS-6766 potently inhibits proliferation of KRAS and BRAF mt cell lines. Focal adhesion kinase (FAK) activation is a putative resistance mechanism to RAF and MEK inhibition, and defactinib, a small molecule FAKi, has shown synergistic anti-tumor activity with VS-6766 in KRAS mt NSCLC models. In a KRAS G12V mt NSCLC mouse model, which was shown to be especially dependent on CRAF, VS-6766 induced strong tumor regressions both as monotherapy and in combination with FAKi (Coma AACR 2021). Clinically, VS-6766 monotherapy has shown responses in KRAS mt NSCLC including pts with KRAS G12V and in pts with BRAF V600E solid tumors (Guo 2020; Martinez-Garcia 2012). The combination of VS-6766 + defactinib is currently being evaluated in the Investigator Sponsored FRAME study. In an updated analysis of response in 20 pts with KRAS mt NSCLC, there were 2 confirmed PRs, 1 unconfirmed PR and 10 SDs (ORR = 15%; DCR = 65%) with 7/20 pts remaining on treatment for ≥24 weeks. The 2 pts with KRAS G12V NSCLC both had confirmed PRs (ORR = 100%). This combination regimen exhibited a manageable safety profile with no NSCLC pts discontinuing for adverse events (Krebs AACR 2021). Methods: This is an international phase 2, adaptive, multicenter, randomized, open label study designed to evaluate the efficacy and safety of VS-6766 vs. VS-6766 + defactinib in pts with recurrent KRAS or BRAF mt NSCLC (NCT04620330). Part A will determine the optimal regimen, either VS-6766 monotherapy or VS-6766 + defactinib based on pts with KRAS G12V. Part A will consist of 5 NSCLC arms: Arm 1 VS-6766 monotherapy in KRAS G12V, Arm 2 VS-6766 + defactinib in KRAS G12V, Arm 3 the combination in KRAS non-G12V, Arm 4 the combination in BRAF V600E and Arm 5 the combination in BRAF non-V600E. Part B will determine the efficacy of the optimal regimen identified in Part A. Pts must have histologic or cytologic evidence of NSCLC, measurable disease according to RECIST V1.1, known KRAS or BRAF mt and at least 1 prior systemic therapy (appropriate therapy for activating mutation and/or platinum-based therapy). Part A will enroll 102 pts Arms 1 and 2 (KRAS G12V), and Arms 4 and 5 (BRAF V600E and non-V600E) are currently open. Arm 3 (KRAS non-G12V) enrollment is completed. The total number of pts in Part B will be determined by results from Part A. Clinical trial information: NCT04620330.
How did Transthyretin Amyloid Cardiomyopathy Progress in Patients Who Took Placebo in the Study ATTR-ACT? a Plain Language Summary
Nativi-Nicolau, José , Hoffman, James E. , Gundapaneni, Balarama, Keohane, Denis, Sultan, Marla B. , Grogan, Martha , Judge, Daniel P.

Mayo Clinic

Future Cardiology | March 17, 2022 | Volume: 18 | Issue: 6 | Pages: 445-453

10.2217/fca-2021-0150 | PMID 35297655 Get It

Using the Child Sheehan Disability Scale to Differentiate Severity Level in Youth With Anxiety Disorders and Obsessive Compulsive Disorder
Whiteside, Stephen P. H. , Riemann, Bradley C. , McCarthy, Denis M.

Mayo Clinic

Assessment | February 21, 2022 | Volume: 30 | Issue: 4 | Pages: 998-1008

10.1177/10731911221077232 | PMID 35187974 Get It

The current study extends the psychometric support for the Child Sheehan Disability Scale (CSDS) as a measure of impairment associated with childhood anxiety disorders, including obsessive compulsive disorder. The CSDS was completed by 1,481 predominately Caucasian youth (55.4% female) ages 8 to 17 ( M = 12.68, SD = 2.78) from primarily two-parent households and a parent across community, outpatient, intensive outpatient treatment, and residential settings. The results replicated and extended the previously found strong convergent validity, discriminant validity, and treatment sensitivity with a revised parent-report item in the larger sample. Moreover, the CSDS successfully differentiated between patients receiving treatment of different levels of intensity. These data were used to develop preliminary qualitative descriptors associating individual scores with a likely level of indicated treatment to enhance the clinical applicability of the CSDS. This study establishes the CSDS as one of the briefest and most rigorously evaluated measures of impairment associated with child anxiety. However, the performance of the CSDS must be examined in more representative samples before being applied to diverse populations.
New Therapy for Spinal Cord Injury: Autologous Genetically-Enriched Leucoconcentrate Integrated with Epidural Electrical Stimulation
Исламов, Р. Р. , Bashirov, F. V , Izmailov, Andrei , Fadeev, Filip , Markosyan, Vage , Sokolov, Mikhail , Шмаров, М. М. , Lavrov, Igor , Islamov, Rustem , Shmarov, Maksim , Lavrov, Igor , Logunov, Denis Y. , Naroditsky, Boris S.

Mayo Clinic

Cells | January 3, 2022 | Volume: 11 | Issue: 1 | Pages: 144

10.3390/cells11010144 | PMID 35011706 Get It

The contemporary strategy for spinal cord injury (SCI) therapy aims to combine multiple approaches to control pathogenic mechanisms of neurodegeneration and stimulate neuroregeneration. In this study, a novel regenerative approach using an autologous leucoconcentrate enriched with transgenes encoding vascular endothelial growth factor (VEGF), glial cell line-derived neurotrophic factor (GDNF), and neural cell adhesion molecule (NCAM) combined with supra- and sub-lesional epidural electrical stimulation (EES) was tested on mini-pigs similar in morpho-physiological scale to humans. The complex analysis of the spinal cord recovery after a moderate contusion injury in treated mini-pigs compared to control animals revealed: better performance in behavioural and joint kinematics, restoration of electromyography characteristics, and improvement in selected immunohistology features related to cell survivability, synaptic protein expression, and glial reorganization above and below the injury. These results for the first time demonstrate the positive effect of intravenous infusion of autologous genetically-enriched leucoconcentrate producing recombinant molecules stimulating neuroregeneration combined with neuromodulation by translesional multisite EES on the restoration of the post-traumatic spinal cord in mini-pigs and suggest the high translational potential of this novel regenerative therapy for SCI patients.